Selective tumor cell killing by triptolide in p53 wild-type and p53 mutant ovarian carcinomas

Medical Oncology

Volumn 31, Issue 7, 2014, Pages

  Wu, Jianyuan ^a   Li, Qingdi Quentin ^b   Zhou, Huiping ^c   Lu, Yinying ^d   Li, Jueli M ^e   Ma, Yao ^a   Wang, Li ^a   Fu, Tingting ^a   Gong, Xingjiang ^a   Weintraub, Michael ^b   Wu, Shuangchan ^a   Ding, Hong ^a,f  

^a WUHAN UNIVERSITY   (China)

^b NATIONAL CANCER INSTITUTE   (United States)

^c VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d BEIJING 302 HOSPITAL   (China)

^e UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

^f HUBEI UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Antitumor drug; Apoptosis; Cell cycle; Ovarian cancer; p53; Triptolide

Indexed keywords

CASPASE 3; CISPLATIN; CYTOCHROME C; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P53; TRIPTOLIDE; ALKYLATING AGENT; BAX PROTEIN, HUMAN; CASPASE; CDKN1A PROTEIN, HUMAN; CYCLIN DEPENDENT KINASE INHIBITOR 1A; DITERPENE; EPOXIDE; PHENANTHRENE DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CARCINOMA CELL; CELL CYCLE ARREST; CELL CYCLE S PHASE; CELL GROWTH; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; DRUG SENSITIVITY; ENZYME ACTIVATION; ENZYME RELEASE; FEMALE; HUMAN; HUMAN CELL; LUNG FIBROBLAST; M PHASE CELL CYCLE CHECKPOINT; MACROPHAGE; OVARY CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; UPREGULATION; CELL CYCLE CHECKPOINT; DRUG EFFECTS; GENETICS; METABOLISM; MITOCHONDRION; MUTATION; OVARIAN NEOPLASMS; PATHOLOGY; PHYSIOLOGY; TUMOR CELL LINE; TUMOR SUPPRESSOR GENE;

ANTINEOPLASTIC AGENTS, ALKYLATING; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; CASPASES; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DITERPENES; EPOXY COMPOUNDS; FEMALE; GENES, P53; HUMANS; MITOCHONDRIA; MUTATION; OVARIAN NEOPLASMS; PHENANTHRENES; PROTO-ONCOGENE PROTEINS C-BCL-2;

EID: 84901579887     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-014-0014-8     Document Type: Article

References (41)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63:11-30.
2. Thaker PH, Deavers M, Celestino J, Thornton A, Fletcher MS, Landen CN, Kinch MS, Kiener PA, Sood AK. EphA2 expression is associated with aggressive features in ovarian carcinoma. Clin Cancer Res. 2004;10:5145-50. (Pubitemid 39099789)
3. Chen YJ, Yuan CC, Chow KC, Wang PH, Lai CR, Yen MS, Wang LS. Overexpression of dihydrodiol dehydrogenase is associated with cisplatin-based chemotherapy resistance in ovarian cancer patients. Gynecol Oncol. 2005;97:110-7.
4. Zhou J, Liu M, Luthra R, Jones J, Aneja R, Chandra R, Tekmal RR, Joshi HC. EM012, a microtubule-interfering agent, inhibits the progression of multidrug-resistant human ovarian cancer both in cultured cells and in athymic nude mice. Cancer Chemother Pharmacol. 2005;55:461-5. (Pubitemid 40568976)
5. Liu Q. Triptolide and its expanding multiple pharmacological functions. Int Immunopharmacol. 2011;11:377-83.
6. Wei YS, Adachi I. Inhibitory effect of triptolide on colony formation of breast and stomach cancer cell lines. Zhongguo Yao Li Xue Bao. 1991;12:406-10.
7. Lou YJ, Jin J. Triptolide down-regulates bcr-abl expression and induces apoptosis in chronic myelogenous leukemia cells. Leuk Lymphoma. 2004;45:373-6. (Pubitemid 38181443)
8. Fidler JM, Li K, Chung C, Wei K, Ross JA, Gao M, Rosen GD. PG490-88, a derivative of triptolide, causes tumor regression and sensitizes tumors to chemotherapy. Mol Cancer Ther. 2003;2:855-62.
9. Frese S, Pirnia F, Miescher D, Krajewski S, Borner MM, Reed JC, Schmid RA. PG490-mediated sensitization of lung cancer cells to Apo2L/TRAIL-induced apoptosis requires activation of ERK2. Oncogene. 2003;22:5427-35. (Pubitemid 37072197)
10. Panichakul T, Wanun T, Reutrakul V, Sirisinha S. Synergistic cytotoxicity and apoptosis induced in human cholangiocarcinoma cell lines by a combined treatment with tumor necrosis factor-α (TNF-α) and triptolide. Asian Pac J Allergy Immunol. 2002;20:167-73. (Pubitemid 36253667)
11. Yang S, Chen J, Guo Z, Xu XM, Wang L, Pei XF, Yang J, Underhill CB, Zhang L. Triptolide inhibits the growth and metastasis of solid tumors. Mol Cancer Ther. 2003;2:65-72.
12. Lee KY, Park JS, Jee YK, Rosen GD. Triptolide sensitizes lung cancer cells to TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis by inhibition of NF-κB activation. Exp Mol Med. 2002;34:462-8. (Pubitemid 36114364)
13. Tengchaisri T, Chawengkirttikul R, Rachaphaew N. Antitumor activity of triptolide against cholangiocarcinoma growth in vitro and in hamsters. Cancer Lett. 1998;133:169-75. (Pubitemid 29069041)
14. Chang WT, Kang JJ, Lee KY, Wei K, Anderson E, Gotmare S, Ross JA, Rosen GD. Triptolide and chemotherapy cooperate in tumor cell apoptosis: a role for the p53 pathway. J Biol Chem. 2001;276:2221-7. (Pubitemid 32109705)
15. Lu X, Errington J, Curtin NJ, Lunec J, Newell DR. The impact of p53 status on cellular sensitivity to antifolate drugs. Clin Cancer Res. 2001;7:2114-23. (Pubitemid 32994852)
16. O'Connor PM, Jackman J, Bae I, Myers TG, Fan S, Mutoh M, Scudiero DA, Monks A, Sausville EA, Weinstein JN, Friend S, Fornace AJ, Kohn KW. Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents. Cancer Res. 1997;57:4285-300. (Pubitemid 27413438)
17. Taniguchi Y, Suzuki K, Nakajima K, Nakajima M, Miwa Y, Yamada Y, Satoh M, Takeyoshi M, Akie Y, Moriyasu M. Interlaboratory validation study of the skin2 dermal model ZK1100 and MTT cytotoxicity assay kits. J Toxicol Sci. 1994;19:37-44. (Pubitemid 24104206)
18. Sievers C, Platt N, Perry VH, Coleman MP, Conforti L. Neurites undergoing Wallerian degeneration show an apoptotic-like process with annexin V positive staining and loss of mitochondrial membrane potential. Neurosci Res. 2003;46:161-9. (Pubitemid 36593279)
19. Lee GS, Ryu KS, Rha JG, Kim SP, Namkoong SE, Han KT. Multiparametric flow cytometric analysis in a breast cancer cell line (MCF-7). J Obstet Gynaecol Res. 2002;28:141-8. (Pubitemid 35021662)
20. Oh SH, Lee BH. A ginseng saponin metabolite-induced apoptosis in HepG2 cells involves a mitochondria-mediated pathway and its downstream caspase-8 activation and Bid cleavage. Toxicol Appl Pharmacol. 2004;194:221-9.
21. Maya R, Oren M. Unmasking of phosphorylation-sensitive epitopes on p53 and Mdm2 by a simple Western-phosphatase procedure. Oncogene. 2000;19:3213-5. (Pubitemid 30455933)
22. Li X, Wang G, Zhao J, Ding H, Cunningham C, Chen F, Flynn DC, Reed E, Li QQ. Antiproliferative effect of β-elemene in chemoresistant ovarian carcinoma cells is mediated through arrest of the cell cycle at the G2-M phase. Cell Mol Life Sci. 2005;62:894-904. (Pubitemid 40655636)
23. Li L, Luan Y, Li X, Tang B, Zhang W, Li D, Zhao J, Wang G, Ding H, Reed E, Li QQ. Demonstration of differential gene expression between sensitive and resistant ovarian tumor cells by fluorescence differential display-PCR analysis. Oncol Rep. 2005;13:793-9.
24. Strait KA, Warnick CT, Ford CD, Dabbas B, Hammond EH, Ilstrup SJ. Histone deacetylase inhibitors induce G2-checkpoint arrest and apoptosis in cisplatinum-resistant ovarian cancer cells associated with overexpression of the Bcl-2-related protein Bad. Mol Cancer Ther. 2005;4:603-11. (Pubitemid 40601842)
25. Singer G, Stohr R, Cope L, Dehari R, Hartmann A, Cao DF, Wang TL, Kurman RJ, Shih IeM. Patterns of p53 mutations separate ovarian serous borderline tumors and low- and high-grade carcinomas and provide support for a new model of ovarian carcinogenesis: a mutational analysis with immunohistochemical correlation. Am J Surg Pathol. 2005;29:218-24. (Pubitemid 40170640)
26. Kiviharju TM, Lecane PS, Sellers RG, Peehl DM. Antiproliferative and proapoptotic activities of triptolide (PG490), a natural product entering clinical trials, on primary cultures of human prostatic epithelial cells. Clin Cancer Res. 2002;8:2666-74. (Pubitemid 34856355)
27. Jiang XH, Wong BCY, Lin MCM, Zhu GH, Kung HF, Jiang SH, Yang D, Lam SK. Functional p53 is required for triptolide-induced apoptosis and AP-1 and nuclear factor-κB activation in gastric cancer cells. Oncogene. 2001;20:8009-18. (Pubitemid 34001562)
28. Wan CK, Wang C, Cheung HY, Yang M, Fong WF. Triptolide induces Bcl-2 cleavage and mitochondria dependent apoptosis in p53-deficient HL-60 cells. Cancer Lett. 2006;241:31-41.
29. Contractor R, Samudio IJ, Estrov Z, Harris D, McCubrey JA, Safe SH, Andreeff M, Konopleva M. A novel ring-substituted diindolylmethane, 1,1-bis[3′-(5-methoxyindolyl)]-1-(p-t-butylphenyl) methane, inhibits extracellular signal-regulated kinase activation and induces apoptosis in acute myelogenous leukemia. Cancer Res. 2005;65:2890-8. (Pubitemid 40490093)
30. Kim R. Recent advances in understanding the cell death pathways activated by anticancer therapy. Cancer. 2005;103:1551-60. (Pubitemid 40490015)
31. Zhang Y, Bhavnani BR. Glutamate-induced apoptosis in primary cortical neurons is inhibited by equine estrogens via down-regulation of caspase-3 and prevention of mitochondrial cytochrome c release. BMC Neurosci. 2005;6:13.
32. Bouton LA, Ramirez CD, Bailey DP, Yeatman CF, Yue J, Wright HV, Domen J, Rosato RR, Grant S, Fischer-Stenger K, Ryan JJ. Costimulation with interleukin-4 and interleukin-10 induces mast cell apoptosis and cell-cycle arrest: the role of p53 and the mitochondrion. Exp Hematol. 2004;32:1137-45. (Pubitemid 39601119)
33. Wang XF, Witting PK, Salvatore BA, Neuzil J. Vitamin E analogs trigger apoptosis in HER2/erbB2-overexpressing breast cancer cells by signaling via the mitochondrial pathway. Biochem Biophys Res Commun. 2005;326:282-9. (Pubitemid 39593544)
34. Doreswamy K, Shrilatha B, Rajeshkumar T, Muralidhara. Nickel-induced oxidative stress in testis of mice: evidence of DNA damage and genotoxic effects. J Androl. 2004;25:996-1003. (Pubitemid 39425607)
35. Kim MS, Kim BJ, Woo HN, Kim KW, Kim KB, Kim IK, Jung YK. Cadmium induces caspase-mediated cell death: suppression by Bcl-2. Toxicology 2000;145:27-37. (Pubitemid 30190264)
36. Huang HM, Ou HC, Xu H, Chen HL, Fowler C, Gibson GE. Inhibition of α-ketoglutarate dehydrogenase complex promotes cytochrome c release from mitochondria, caspase-3 activation, and necrotic cell death. J Neurosci Res. 2003;74:309-17. (Pubitemid 37193717)
37. Abramova NA, Cassarino DS, Khan SM, Painter TW, Bennett JP. Inhibition by R(+) or S(-) pramipexole of caspase activation and cell death induced by methylpyridinium ion or beta amyloid peptide in SH-SY5Y neuroblastoma. J Neurosci Res. 2002;67:494-500. (Pubitemid 34117119)
38. Park SY, Cho SJ, Kwon HC, Lee KR, Rhee DK, Pyo S. Caspase-independent cell death by allicin in human epithelial carcinoma cells: involvement of PKA. Cancer Lett. 2005;224:123-32. (Pubitemid 40720373)
39. Pan J. RNA polymerase: an important molecular target of triptolide in cancer cells. Cancer Lett. 2010;292:149-52.
40. Wang Z. Triptolide downregulates Rac1 and the JAK/STAT3 pathway and inhibits colitis-related colon cancer progression. Exp Mol Med. 2009;41:717-27.
41. Zhao F. Triptolide alters histone H3K9 and H3K27 methylation state, and induces G0/G1 arrest and caspase-dependent apoptosis, in multiple myeloma in vitro. Toxicology. 2010;267:70-9.